Avantor opened higher at $16.74, compared with its previous close of $16.68. In the last trading session, the stock traded between $15.88 and $16.80. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Avantor is now worth
$ 39.51
resulting in a loss of
$ 60.49 (60.49%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 12 Analysts
Buy
8.33%
Hold
83.33%
Sell
8.33%
Markets Today
Today's Change
$-0.72 (-4.34%)
Day High
$16.80
Day Low
$15.88
Day Open
$16.74
Prev Close
$16.68
Volume
39,80,838
1W Return
-6.95%
1M Return
4.64%
3M Return
11.01%
6M Return
103.26%
1Y Return
37.79%
Fundamentals
Market Cap ($ Mn)
10,812
PE Ratio
-
PB Ratio
1.75
PEG Ratio
-
ROE
-8.99%
ROCE
-2.65%
EPS (TTM)
$0.30
Investment Returns
1 Week
-6.95%
1 Month
4.64%
3 Months
11.01%
6 Months
103.26%
9 Months
47.60%
Financials
Quarterly
All values in $ Mn
1.7K
Jun 25
1.6K
Sep 25
1.7K
Dec 25
1.6K
Mar 26
1.7K
Jun 26
1.7K
Sep 26
Updates
29Jul
Avantor raises FY26 adj EPS guidance to $0.80-$0.83 on strong Q2
Avantor Inc raised its fiscal 2026 adjusted EPS guidance to $0.80-$0.83, surpassing analyst estimates, following a Q2 revenue beat of $1,692.3 million. The company also updated its organic revenue growth guidance to -0.5% to +0.5%, driven by strong performance in the VWR Distribution & Services segment.
3mo ago
14Jul
Avantor's NuSil expands partnership to develop three-month HIV prevention ring
Avantor's NuSil brand has expanded its partnership with the Population Council to develop a three-month dapivirine vaginal ring for HIV prevention. The new ring aims to improve adherence and reduce costs by requiring only four doses per year instead of twelve. Clinical studies indicate higher drug delivery levels compared to the monthly version. Regulatory review was submitted to the European Medicines Agency in November 2025.
3mo ago
9Jul
Citigroup maintains Neutral on Avantor, raises target to $11
Citigroup analyst Patrick Donnelly maintained a Neutral rating on Avantor and raised the price target to $11 from $9, reflecting a revised valuation outlook.
3mo ago
26Jun
Bernstein reinstates Avantor with Market Perform, $10.5 target
Bernstein analyst Eve Burstein reinstated coverage of Avantor with a Market Perform rating and a $10.5 price target, replacing the previous Underweight rating and $8 target from Barclays.
